Magellan Bioanalytics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Magellan Bioanalytics is a private, pre-revenue software company providing an AI-powered analytical platform for mass spectrometry-based proteomics and diagnostics. Founded by former professors with expertise in cell biology and computer science, the company addresses the critical bottleneck of data analysis in large-scale omics studies. Its core offering, the COMPASS software suite, uses machine learning to accelerate and deepen insights from mass spec data, with future plans including a next-generation data repository and a proprietary omics data archive. The company operates on a platform and services business model, targeting the growing market for advanced bioinformatics in life sciences research.

DiagnosticsProteomics

Technology Platform

AI and machine learning software platform for comprehensive, rapid analysis of mass spectrometry data, enabling comparative expression analysis across complex proteomics and omics datasets.

Opportunities

The growing adoption of proteomics and multi-omics in drug discovery and diagnostics creates a large, underserved need for advanced data analysis tools.

Magellan's platform-agnostic approach allows it to serve a broad market across different mass spec technologies.

The planned data repository and archive could create valuable network effects and proprietary data assets.

Risk Factors

Facing intense competition from both established bioinformatics vendors and agile startups.

Market adoption may be slow as researchers are often entrenched in existing, sometimes free, analysis pipelines.

As a pre-revenue private company, it is dependent on external funding and must achieve product-market fit to reach sustainability.

Competitive Landscape

Magellan competes in the bioinformatics software market for mass spectrometry, which includes instrument vendors' software (e.g., Thermo Fisher, SCIEX), independent software providers (e.g., ProteinMetrics, Spectronaut), and open-source platforms (e.g., MaxQuant, Skyline). Its key differentiator is its emphasis on AI/ML for comprehensive, rapid comparative analysis across large, complex sample sets.

More companies in AI / Machine Learning →More companies in United States →